• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Have You Heard This (Week's) News?

News
Poll

Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.

Eylea (aflibercept) injection is also indicated for treatment of which of the following?

A. Neovascular age-related macular degeneration
B. Macular edema following retinal vein occlusion
C. Both of the above
Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Model Predicts Complications of T2D and Progression Based on Risk Factors

Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control

Grace Halsey
October 30th 2025
Article

The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

Grace Halsey
October 27th 2025
Article

After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose / Image credit: ©New Africa/AdobeStock

Real-Time CGM Reduces Risk of Large Newborns in Gestational Diabetes: Daily Dose

Sydney Jennings
October 16th 2025
Article

Your daily dose of the clinical news you may have missed.

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D / image credit ©Gecko Studio/stock.adobe.com

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D

Grace Halsey
October 15th 2025
Article

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

© 2025 MJH Life Sciences

All rights reserved.